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ABSTRACT: Background: Hypertension is a modifiable
cardiovascular risk factor implicated in neurodegeneration
and dementia risk. In Huntington’s disease, a monogenic
neurodegenerative disease, autonomic and vascular abnor-
malities have been reported. This study’s objective was to
examine the relationship between hypertension and dis-
ease severity and progression in Huntington’s disease.
Methods: Using longitudinal data from the largest
worldwide observational study of Huntington’s disease
(n = 14,534), we assessed the relationship between hyper-
tension, disease severity, and rate of clinical progression
in Huntington’s disease mutation carriers. Propensity
score matching was used to statistically match normoten-
sive and hypertensive participants for age, sex, body
mass index, ethnicity, and CAG length.
Results: Huntington’s disease patients had a lower
prevalence of hypertension compared with age-matched
gene-negative controls. Huntington’s disease patients with
hypertension had worse cognitive function, a higher depres-
sion score, and more marked motor progression over time
compared with Huntington’s disease patients without
hypertension. However, hypertensive patients taking
antihypertensive medication had less motor, cognitive,
and functional impairment than Huntington’s disease
patients with untreated hypertension and a later age of
clinical onset compared with untreated hypertensive
patients and normotensive individuals with Huntington’s
disease.
Conclusions: We report the novel finding that hyperten-
sion and antihypertensive medication use are associated
with altered disease severity, progression, and clinical
onset in patients with Huntington’s disease. These find-
ings have implications for the management of hyperten-
sion in Huntington’s disease and suggest that prospective
studies of the symptomatic or disease-modifying potential
of antihypertensives in neurodegenerative diseases are
warranted. © 2020 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Interna-
tional Parkinson and Movement Disorder Society.
Key Words: blood pressure; cardiovascular risk; hyper-
tension; neurodegeneration
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Huntington’s disease (HD) is a neurodegenerative
disorder caused by the expansion of a CAG repeat
sequence in exon 1 in the Huntingtin gene,1,2 leading to
the expression of mutant huntingtin (mHtt) protein
containing an expanded polyglutamine stretch. The ear-
liest and most marked brain change is striatal atrophy,
although more widespread changes are increasingly
seen with disease progression.3-5 Alongside the charac-
teristic triad of cognitive, behavioral, and movement
deficits,6 a range of symptoms suggestive of autonomic
nervous system (ANS) dysfunction have been shown to
exist in patients with HD. For example, excessive
sweating, micturition difficulties, orthostatic intoler-
ance, sexual dysfunction, gastrointestinal problems,
and tachycardia have been reported in patients across
disease stages, including premanifest gene carriers,7-10
suggesting that autonomic symptoms contribute to the
clinical phenotype of HD and disease burden.
The autonomic nervous system plays a fundamental
role in modulating cardiovascular functions, including
the control of blood pressure.11 Hypertension and dis-
turbances in blood pressure regulation have been asso-
ciated with Parkinson’s disease12-14 and Alzheimer’s
disease,15 whereas peptides of the renin-angiotensin sys-
tem, a prominent therapeutic target in hypertension,
have been implicated in the pathophysiology of neuro-
degenerative diseases16 including HD, suggesting that
hypertension impacts the neurodegenerative process.
Despite this, the functioning of the ANS has been rela-
tively underexplored in HD. Neuronal inclusion bodies
of mHtt occur throughout the hypothalamus,17 which is
a key hub for autonomic regulation. A handful of studies
to date have shown evidence of ANS dysfunction,18-20
with some evidence that both the sympathetic and para-
sympathetic branches of the ANS are affected,19,21
whereas others have shown evidence of intact or even
increased sympathetic activity.22 Kobal et al20 carried
out a battery of cardiovascular autonomic testing in HD
patients and found an effect of HD disease stage on auto-
nomic functioning. Premanifest HD gene carriers were
found to have a higher Valsalva ratio and higher low-
frequency power of the heart rate variability spectrum
compared with controls, whereas early-stage manifest
HD patients displayed a higher sympathovagal ratio,
which together suggest higher sympathetic activity in
early stages of the disease. In contrast, HD patients with
more advanced stages of the disease were found to have a
smaller increase in diastolic blood pressure during a
handgrip along with a decreased respiratory and ortho-
static ratio.20
Although the most prominent symptoms of HD are
related to the central nervous system, mHtt is ubiqui-
tously expressed in human tissue,2 prompting more
attention to be paid to the possible involvement of non-
CNS tissues and organs.23-25 The vascular contribution
to HD pathology is increasingly recognized4,26 and
thought to involve multiple pathogenic pathways.27-29
Nevertheless, little is known about the prevalence and
clinical effect of cardiovascular risk factors such as hyper-
tension on patients with HD. This is important, as evi-
dence shows that both genetic and environmental factors
can modify the age at onset and disease course in
HD.30,31 Previous work using the Registry database, a
European subset of the worldwide Enroll-HD data set,32
showed a paradoxical delay in the clinical onset of HD in
patients with hypertension, although the potentially con-
founding effects of age, sex, and body mass index
(BMI)33-35 were not accounted for. Here, we used data
from Enroll-HD, which is the global follow-on study
from Registry and comprises more extensive and more
stringently monitored data. We statistically matched
normotensive HD patients with HD patients with hyper-
tension based on age, sex, BMI, ethnicity, and poly-
glutamine expansion length to comprehensively
characterize the effect of hypertension on HD symptom
severity and progression while accounting for con-
founding variables.
Methods
Participants
Enroll-HD is a multicenter longitudinal observational
study designed to facilitate clinical research in HD. Core
data sets are collected annually. We retrieved the fourth
periodic version of the Enroll-HD database (version 2.0),
which contained observational data from 15,301 partici-
pants (55.6% female, 3539 premanifest HD, 8043manifest
HD, 3629 gene-negative and/or family controls at baseline;
50,452 visits in total) and integrated longitudinal data from
5355 individuals who had previously participated in the
Registry study. Data were monitored for quality and accu-
racy using a risk-basedmonitoring approach.
All participating sites were required to obtain and
maintain local ethics committee approval, and all partici-
pants gave signed informed consent for their data to be
included in accordance with the Declaration of Helsinki.
Participants aged younger than 18 years old at their
baseline visit were excluded. HD participants with a
CAG length recorded as >70 were excluded, as the pre-
cise length was not available. Manifest HD status was
determined by the rater and expressed as a diagnostic
confidence level of 4, indicating unequivocal motor
signs of HD (≥99% confidence).
Hypertension Status
Participants with a current diagnosis of essential (pri-
mary) hypertension (I10) were coded using the Interna-
tional Classification of Diseases (10th revision), which
excludes hypertension complicating pregnancy, neonatal
hypertension, primary pulmonary hypertension, and pri-
mary and secondary hypertension involving vessels of the
2 Movement Disorders, 2020
S T E V E N T O N E T A L
brain or eye and those with comorbid heart or kidney dis-
ease. Hypertensive participants with a history of antihy-
pertensive medication use but whose treatment was not
ongoing were excluded from the analyses focused on
medication effects. Antihypertensive medication was
coded using the Anatomical Therapeutic Chemical classi-
fication system (see Supplementary information).
Clinical Outcome Measures
Performance on motor, functional, behavioral, and
cognitive subdomains of the Enroll-HD assessment
were used as a measure of disease severity and progres-
sion. Full details can be found in the study protocol at
https://www.enroll-hd.org/.
The measures of interest were total motor score
(TMS), depression and anxiety score on the Hospital
Anxiety and Depression Scale, total functional capacity
(TFC), and all the Unified Huntington’s Disease Rating
Scale cognitive subdomains.36 TFC is a measure of
capacity to work, handle finances, perform chores and
self-care, and live independently, and the scale ranges
from 13 (normal) to 0 (severe disability).
The 4 cognitive subtests were: Stroop (word reading,
color naming, and interference), Trail Making (parts A
and B), Verbal Fluency (categories and letter), and the
Symbol Digit Modalities Test. Additional details can be
found in the Supplementary Information.
Statistical Analysis
Statistical analysis was performed using the open-
source software RStudio (version 1.1.463), and the
code used can be accessed at http://doi.org/10.17035/d.
2019.0079578885.
Age, BMI, sex, and ethnicity were identified as a priori
confounding variables.35,37,38 Propensity score matching
with nearest neighbor matching was used to match (2:1
ratio) the 2 groups of interest and adjust for confounds.39,40
Propensity scores were calculated using age, BMI, sex, and
ethnicity, along with CAG length for HD-specific analysis;
the resulting sample size and demographics of included
patients for each analysis are shown in Table 1. Supplemen-
tary Tables 1–3 show the demographics after stratifying for
antihypertensive medication use. Following matching, if the
standardized mean difference (SMD) between groups was
greater than 0.10 or P < 0.01, the variable was demeaned
and added as a covariate in the regression model to remove
residual confounding bias.41
The prevalence of hypertension in HD participants
compared with matched controls was statistically tested
using a logistic regression, with confounding factors
included to determine potential independent risk factors
for hypertension. Where significant, a Wald test assessed
each variable’s contribution to the model.
In all analyses except age at onset, premanifest and
manifest HD participants were included. Multiple
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comparisons were adjusted using the false-discovery
rate (q = 0.05).42 To reduce the dimensionality of the
cognitive scores, we performed a principal components
analysis (n = 4578) on the 8 standardized and trans-
formed cognitive subdomain scores to derive a sum-
mary statistic that could capture most of the variation.
The first principal component (PC1) accounted for
60.01% of the variation and was used as a dependent
variable.
A linear regression analysis examined the effect of
hypertension (normotensive vs hypertensive) and anti-
hypertensive medication status (levels: normotensive,
treated hypertensive, untreated hypertensive) on base-
line measures. Post hoc pairwise comparisons applied a
P = 0.05 Tukey-adjusted significance level.
To examine the interaction between hypertension and
clinical progression over time, we applied linear mixed-
effects models using the lme4 package with fixed and
random terms to account for the correlation between
the repeated measurements for each individual and visit
day as the time variable.
Results
Group demographics for each analysis after propensity
matching are shown in Table 1. For the longitudinal
analysis, the mean visit day was 468  464 days, with a
range from 0 to 2184 days (see Supplementary Fig. 1).
Demographics of the Cohort by Hypertension
Diagnosis
Table 2 shows the demographics of the Enroll-HD
database; 2248 participants (15.5%) had a diagnosis of
essential hypertension, and of these, 1697 (75.5%)
were currently prescribed antihypertension medication.
Hypertensive participants were older, had a higher
BMI, a lower CAG repeat length, and a lower female:
male ratio. Manifest HD participants were older and
had a lower BMI compared with premanifest HD and
control participants, and premanifest HD participants
were younger with a lower BMI than control partici-
pants (all P < 0.0001), justifying the use of propensity
matching to account for confounding variables. Across
the course of the study there was no difference in the
frequency of death between normotensive and hyper-
tensive HD participants (P = 0.997).
Hypertension in HD
BMI and ethnicity were included in the regression
model (SMD > 0.1). The prevalence of essential hyper-
tension was lower in HD patients (premanifest and
manifest HD combined, 13.85%) compared with con-
trols (19.34%; z = 5.60, P = 2.12 × 10−8). Independent
of HD status, BMI (z = 20.40, P < 2 × 10−16) and
ethnicity (χ2 = 16.0, P = 0.014) were associated with
hypertension prevalence.
Examining risk factors for hypertension, we paradox-
ically found that HD patients consumed more units of
alcohol (95% CI, 0.85–1.84 units per week;
P = 1.23 × 10−7), smoked more cigarettes (95% CI,
0.91–2.22 cigarettes/day; P = 3.06 × 10−6), and had
been smoking for more years (95% CI, 0.18–1.72 years;
P = 0.015) compared with controls.
Hypertension and Disease-Onset Age
Normotensive HD patients were diagnosed with clini-
cal onset an average of 1.5 years earlier than hyperten-
sive HD patients (F1,3402 = 15.68, 95% CI,
0.75–2.21 years; P = 7.66 × 10−5). Follow-up analyses
comparing treated hypertensives (n = 908) and
untreated hypertensives (n = 297) with normotensive
HD patients (n = 2410) are shown in Figure 1A; treated
hypertensives had an onset age 2.04  0.41 years later
than normotensives (P < 0.0001) and 2.25  0.71 years
later than untreated hypertensives (P = 0.004), whereas
untreated hypertensives did not differ from normoten-
sives (0.22  0.65 years, P = 0.94).
Hypertension and Motor Symptom Severity
A higher motor score is indicative of more motor
impairment. At the baseline visit, there was no differ-
ence in motor score (TMS) between normotensives and
hypertensives (F1,4508 = 0.76, P = 0.38; Fig. 1), whereas
longitudinally, there was an interaction between time
and hypertension status (95% CI, 0.00015–0.0011;
P = 0.011; see Fig. 2A). Based on the findings related to
HD disease onset, we analyzed TMS in premanifest HD
and manifest HD participants separately and again did
not find an association with hypertension (P = 0.35 and
0.12, respectively).
TMS was 3.51  1.30 points higher in untreated
hypertensive HD participants than in HD participants
taking medication for hypertension (P = 0.019; see
Fig. 1B) and 3.17  1.19 points higher than in normo-
tensives (P = 0.021), whereas there was no difference in
motor score between treated hypertensives and normo-
tensives (0.34  0.776, P = 0.89).
The change in TMS over time was greater in untreated
hypertensives (n = 372) compared with treated hyperten-
sives (n = 1144, 2.88  1.09, P = 0.02; Fig. 2B) and nor-
motensives (n = 3032, 2.47  0.99, P = 0.03) and did not
differ between normotensive and treated hypertensive HD
patients (P = 0.79). The duration of antihypertensive med-
ication use did not predict motor score in treated hyper-
tensive HD participants (F1,1558 = 0.16; 95% CI, −0.01
to 0.008; P = 0.69). Furthermore, for patients for whom
HD onset occurred prior to hypertension diagnosis
(n = 551), there was no difference in motor score between
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FIG. 1. Effect of hypertension and associated antihypertensive treatment on HD clinical markers. Data shown are estimated marginal means (EMMs);
black dot represents the mean, blue bars are 95% CIs for the EMMs, red arrows represent the Tukey-based statistical comparison (overlapping arrows
= notsignificant). ***p-values < 0.001, **p-values < 0.01, *p-vales < 0.05. Normo = Normotensive, Untreated = Hypertensive patient not taking antihy-
pertensive medication, PC1 = Cognitive summary statistic from the principal component analysis, principal component 1. [Color figure can be viewed
at wileyonlinelibrary.com]
FIG. 2. Disease progression in the motor (A-B) and functional domain (C-D) based on hypertension status (left panels) and treatment status (right
panels). 95% confidence level interval for predictions from a linearmodel are displayed. *p < 0.05 from Tukey-based statistical comparison. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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treated (n = 430) and untreated (n = 121) hypertensives
(estimate = −1.11  1.79; P = 0.93).
Hypertension and Total Functional Capacity
A higher total functional capacity (TFC) is indicative
of better functional ability. After matching, there was no
difference in TFC between hypertensives and normoten-
sives at baseline (F1,4567 = 0.11, P = 0.74). Longitudi-
nally, there was an interaction between hypertension and
time (95% CI, −1.02 to −0.0002; P = 0.029; Fig. 2C).
Baseline TFC was lower in untreated hypertensive
HD patients compared with treated hypertensive HD
patients (0.61  0.22 points, P = 0.02) and with
normotensives (0.50  0.20, P = 0.04), with no
difference in TFC between treated hypertensives and
normotensives (P = 0.67).
Longitudinally, untreated hypertensives had a
steeper decline in TFC compared with treated hyper-
tensives (−0.48  0.19, P = 0.031) and normotensives
(−0.43  0.17, P = 0.034), with no difference between
normotensive and treated hypertensives (P = 0.83, see
Fig. 2D).
Hypertension and Cognition
At baseline, hypertension had a significant effect on
the cognitive summary score represented by PC1
(F1,4575 = 6.66; 95% CI, −0.24 to −0.03; P = 0.010),
whereas there was no effect of hypertension on PC1
over time (P = 0.24). At baseline, hypertensive HD
patients performed worse on the Letter Verbal Fluency
and Trail Making (part B) tests (FDR-adjusted
P = 0.017 and 0.015, respectively). There was an inter-
action between hypertension status and time for perfor-
mance on the Trail Making A subtest (95% CI,
0.005–0.002 seconds; P = 0.0017 FDR-adjusted).
Antihypertensive treatment was associated with PC1
(F1,4574 = 8.34, P = 0.0002; see Fig. 1C) and all the
cognitive subdomain tests, except for the Stroop Inter-
ference test (see Table 3). Untreated hypertensives had
a lower PC1 score compared with normotensives
(P = 0.0001) and treated hypertensives (P = 0.005),
whereas the PC1 score was similar for treated hyperten-
sive patients and normotensives (P = 0.57). Compared
with normotensives and treated hypertensive patients,
untreated hypertensive patients performed worse on the
Symbol Digit Modalities Test, the Semantic Fluency
test, and the Stroop word reading and color-naming
subtests (all P < 0.05). Untreated hypertensives were
also significantly slower on both versions of the Trail
Making test compared with normotensives. In contrast,
treated hypertensives performed at a level similar to
normotensives on all tests (all P > 0.05) except the Let-
ter Verbal Fluency test (P = 0.05).
Over time, performance on Trail Making A and B dif-
fered between normotensive HD participants and
untreated hypertensives (A, −8.68  2.96; P = 0.009; B,
−14.43  3.81; FDR-adjusted P = 0.004; Fig. 2F), and
between normotensives and treated HD participants on
subtest A (−6.49  2.38, P = 0.018; Fig. 2F), whereas
there was no difference between treated and untreated
hypertensives (all P > 0.05). For PC1, there was a differ-
ence between normotensives and untreated hypertensives
(0.29  0.09, P = 0.003) and between treated and
untreated hypertensives (0.24  0.10, P = 0.034), yet no
difference between treated hypertensives and normoten-
sives (P = 0.68).
Hypertension and Depression in HD
Hypertensive HD patients had a higher depression
score (F1,2585 = 13.66; 95% CI, 0.31–1.0; P = 0.0002)
and higher anxiety score (F1,2580 = 9.52; 95% CI,
0.19–0.87; P = 0.002) compared with normotensive
HD patients. For 7.7% of hypertensive HD partici-
pants, there was a comorbid diagnosis of ongoing
recurrent depression compared with 5.5% in
TABLE 3. Cognitive subscores (estimated marginal mean  standard error of the mean, accounting for age) for HD patients
with and without a diagnosis of essential hypertension from the baseline Enroll visit and with and without antihypertensive
medication
Pairwise comparison (P)
Normotensive Untreated hypertensive Treated hypertensive Normo-untreated Normo-treated Untreated-treated
Symbol Digit 26.8  0.27 23.5  0.78 26.4  0.44 0.0002 0.79 0.003
Letter Verbal Fluency 25.2  0.32 23.1  0.91 23.7  0.52 0.088 0.049 0.83
Semantic Fluency 13.3  0.12 12.3  0.34 13.3  0.19 0.019 0.999 0.038
Stroop Word Reading 55.6  0.44 50.9  1.25 55.9  0.71 0.001 0.94 0.002
Stroop Colour Naming 45.6  0.36 41.9  1.03 45.5  0.58 0.003 0.99 0.008
Stroop Interference 25.8  0.25 24.5  0.71 25.0  0.40 0.20 0.21 0.81
Trail Making A (s)a 66.8  1.14 75.8  3.26 68.0  1.83 0.03 0.83 0.10
Trail Making B (s)a 135  1.59 148  4.54 141  2.56 0.01 0.06 0.36
Normo, normotensive.
Boldface P values represent those that are statistically significant.
aA high time score on the Trail-Making tests represents worse performance.
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normotensive HD participants (age-adjusted odds ratio,
1.44; 95% CI, 1.12–1.83; P = 0.004).
Normotensive HD participants had a lower depression
and anxiety score compared with treated hypertensive
HD participants (depression: 95% CI, −0.18 to −0.94;
P = 0.01; anxiety: 95% CI, −0.12 to −0.87; P = 0.02;
Fig. 1D) and a lower depression score compared with
untreated hypertensives (95% CI, −0.32 to −1.53;
P = 0.008). There was no difference between treated and
untreated hypertensive HD participants for depression
and anxiety scores (P = 0.52 and 0.89, respectively) and
no difference in anxiety scores between normotensive
and untreated hypertensives (P = 0.08).
There was no interaction between hypertension and
time for depression scores (95% CI, −0.0003 to
0.0002; P = 0.23; data not shown) or for anxiety scores
over time (95% CI, −3.88 × 10−5 to 4.48 × 10−4;
P = 0.10). Similarly, antihypertensives were not associ-
ated with depression or anxiety scores over time
(P = 0.22 and 0.08, respectively, data not shown).
Antihypertensive Medication
We compared hypertensive HD patients prescribed
angiotensin-converting enzyme inhibitors (31.0%),
angiotensin receptor blockers (15.7%), beta-blocking
agents (18.0%), calcium channel blockers (17.2%), and
diuretics (11.7%). The type of antihypertensive class
had no effect on motor score (P = 0.68), age at onset
(P = 0.26), TFC (P = 0.10), depression score (P = 0.78),
anxiety score (P = 0.32), or performance on any cogni-
tive test (all P > 0.05 FDR-adjusted). Estimated mar-
ginal means are shown in Supplementary Figure 2.
Discussion
Using rich longitudinal data from the largest observa-
tion study in HD, we present novel insights into the
association between hypertension — a cardiovascular
risk factor implicated in neurodegeneration — and HD
disease severity and progression. Hypertension was det-
rimentally associated with HD disease severity in the
cognitive and psychiatric domain and with motor
symptom progression over time. Paradoxically, hyper-
tension was also associated with a significant delay in
the age at clinical HD onset in hypertensive patients.
These observed differences between normotensive and
hypertensive HD patients appear to be driven by anti-
hypertensive medication use; hypertensive HD patients
not receiving antihypertensive treatment had worse
motor, cognitive, and functional capacity and more
marked symptom progression over time compared with
normotensive HD patients and hypertensive patients
treated with antihypertensive medication, with potential
implications for the clinical management of hyperten-
sion in HD.
The prevalence of hypertension was lower in HD
patients despite HD patients consuming more alcohol
and tobacco compared with age- and sex-matched con-
trols, both of which are risk factors for developing
hypertension. This novel finding may be driven by dif-
ferences in body mass between the groups; weight loss
is a clinical feature of HD, and HD participants had a
lower body mass index (BMI) than controls, despite
propensity matching. In support of this, BMI was inde-
pendently associated with hypertension prevalence. An
earlier age at death in HD patients may have contrib-
uted to the finding, with fewer participants reaching the
age at which hypertension develops. Alternatively, it
may suggest that mutant Huntingtin has a protective
effect on blood pressure homeostasis, plausibly a conse-
quence of poor sympathoexcitatory pathways and poor
autonomic control. This is in agreement with previous
findings of orthostatic dizziness and a decreased ortho-
static ratio in patients with moderate to severe HD.20
The paradoxical finding of a later age at clinic onset
in hypertensive HD patients has been reported previ-
ously in a European subset cohort (n = 630) of the cur-
rent worldwide data set32; however, this study did not
statistically account for the confounding effects of age,
sex, and BMI, which affect hypertension prevalence
and HD disease progression.34,43-45 Here we replicated
the finding in this larger worldwide data set and across a
wide distribution of CAG lengths while controlling for
confounds. Crucially, we also showed that the delay in
onset age was only associated with hypertensives taking
antihypertensive medication, whereas untreated hyperten-
sives had an age at disease onset similar to normotensives.
One interpretation of these results is that either anti-
hypertensive medication, or the lowering of blood pres-
sure is driving the delay in onset age, with a currently
unknown mechanism and implications for HD manage-
ment. Alternatively, the increasing prevalence of hyper-
tension with increasing age may be biasing the data.
For example, a patient with early HD onset is more
likely to have faster disease progression and die earlier
than a patient with later disease onset, which means
that the normotensive group is skewed toward an ear-
lier age at onset, with early-onset patients less likely to
live sufficiently long to develop hypertension. However,
this does not explain the difference in HD onset age
between treated and untreated hypertensives, for whom
there was no difference in age prior to propensity
matching. Furthermore, there was no difference in the
frequency of death during the course of the longitudinal
study between normotensive and hypertensive HD par-
ticipants, suggesting that bias in the data is a less likely
explanation.
Previous work, albeit equivocal, suggests that antihyper-
tensive medication may bestow a neuroprotective effect
for neurodegeneration, with evidence in Alzheimer’s
and Parkinson’s diseases,46-48 whereas to the best of our
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knowledge the current study is the first to examine antihy-
pertensive medication use in HD patients. Hypertensive
HD patients who were not taking antihypertensive medi-
cation had more motor, cognitive, and functional impair-
ment and an earlier age at clinical HD onset than
hypertensive patients receiving treatment to control their
blood pressure, whereas treated hypertensive patients had
disease scores similar to normotensives. Increasing evi-
dence shows that the cerebrovasculature is perturbed in
HD4,26,49; thus, the detrimental effect of uncontrolled
hypertension in HD may be because of a loading effect of
hypertension-induced cerebrovascular pathology on a
weakened vascular system, with further work necessary to
test this hypothesis.
Intriguingly, hypertensive patients with HD were pre-
scribed a variety of different medications acting on dif-
ferent pathways. Angiotensin receptor blockers and
calcium channel blockers are common antihypertensive
treatments shown to have neuroprotective effects.50-53
Here, we found no difference in onset age, motor score,
or functional capacity between hypertensive HD patients
prescribed different classes of antihypertensive medica-
tion, although a lack of sensitivity of these measures to
neuropathology could explain this. Furthermore, we did
not have the statistical power to account for pharmaco-
logical interactions between antihypertensives and other
therapies used to manage the myriad evolving symptoms
over the disease course of HD, yet this will be an impor-
tant consideration for translation to clinical practice.
Mechanistically, it is not clear whether the detrimen-
tal effect of uncontrolled high blood pressure or the
protective effect of antihypertensive medication is driv-
ing our findings, or their combination. The duration of
antihypertensive medication use was not related to
motor score, which may suggest that the reduced motor
impairment observed in the treated hypertensives was
driven by a reduction in high blood pressure. However,
a shortcoming of this study was the lack of blood pres-
sure measurements to determine if the antihypertensive
medication controlled blood pressure. Crucially, these
results identified an association between hypertension,
antihypertensives, and HD disease severity, progression,
and onset yet did not allow inference about causality.
Further work should focus on establishing if a causal
relationship exists, given the current lack of disease-
modifying therapies currently available for HD.
In conclusion, antihypertensive medication was associ-
ated with reduced disease severity for all clinical mea-
sures in hypertensive HD patients. Further investigation
into the therapeutic efficacy of antihypertensive medica-
tion in cases of prehypertension in HD and in pre-
manifest HD is warranted, along with the combinatorial
effect with other HD symptom management therapeu-
tics. This represents an exciting future avenue to explore
the repurposing of specific antihypertensive drugs for the
treatment of neurodegenerative disease.
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